Picture of Kopran logo

KOPRAN Kopran Share Price

0.000.00%
in flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapNeutral

Momentum

Relative Strength (%)
1m+5%
3m-5.77%
6m-8.12%
1yr+14.66%
Volume Change (%)
10d/3m+15.42%
Price vs... (%)
52w High-12.68%
50d MA+3.16%
200d MA+3.02%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital11.73%
Return on Equity10.95%
Operating Margin10.01%

Financial Summary

Year End 31st MarUnit202020212022202320242025E2026ECAGR / Avg
Total RevenueIN₹m3,594.994,918.144,775.215,509.876,145.92n/an/a11.42%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%-10.64+186.88-3.44-58.99+86.77n/an/an/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Mar 202531st Mar 2026
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2025 / 2026

Blurred out image of Kopran EPS forecast chart

Profile Summary

Kopran Limited is an India-based integrated pharmaceutical company. The Company is primarily engaged in the business of manufacturing of formulation (finished dosage form) and active pharmaceutical ingredients (APIs). Its formulations product categories include penicillin-based finished oral dosage forms and non-penicillin-based finished oral dosage forms. The Company's penicillin-based finished oral dosage forms include anti-infective, amoxycillin, ampicillin, cloxacillin and amoxy clauv. Its non-penicillin-based finished oral dosage forms include macrolides, anti-hypertensive, cardiovascular, anti-helmentics, antihistamine, anti-diabetic, pain management and gastroenterology. It provides ingredients in a wide range of pharmaceutical products, such as capsules, injectables and tablets, among others. The Company's APIs products include anti-hypertensive, macrolides, neuromodulator, urological, anti-infective/anti-acne, sterile carbapenems and sterile cephalosporins.

Directors

Last Annual
March 31st, 2024
Last Interim
March 31st, 2024
Incorporated
April 26th, 1958
Public Since
November 17th, 1992
No. of Employees
394
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
in flag iconNational Stock Exchange of India
Shares in Issue
48,210,605

KOPRAN Share Price Performance

Upcoming Events for KOPRAN

Q1 2025 Kopran Ltd Earnings Release

Kopran Ltd Annual Shareholders Meeting

Q2 2025 Kopran Ltd Earnings Release

Similar to KOPRAN

Picture of Aarey Drugs and Pharmaceuticals logo

Aarey Drugs and Pharmaceuticals

in flag iconNational Stock Exchange of India

Picture of Aarti Drugs logo

Aarti Drugs

in flag iconNational Stock Exchange of India

Picture of Aarti Pharmalabs logo

Aarti Pharmalabs

in flag iconNational Stock Exchange of India

Picture of Abbott India logo

Abbott India

in flag iconNational Stock Exchange of India

Picture of Accent Microcell logo

Accent Microcell

in flag iconNational Stock Exchange of India

FAQ